Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for -Mutated NSCLC After Complete Resection.

Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA -mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation strategy warrants further investigation.

Methods: From January 2019 to December 2022, 71 patients with stages I to III NSCLC and (exon 19 deletion or L858R) mutations were enrolled in this observational study.

Causal relationship between inflammatory cytokines, metabolites, and ulcers of lower limb: A Mendelian randomization study.

Inflammatory cytokines are key indicators affecting the development of ulcers of lower limb. The causal role of inflammatory cytokines in ulcers of lower limb and whether this can be mediated by metabolites remain unknown. We conducted a two-step, two-sample Mendelian randomization (MR) study to investigate the causal effect of inflammatory cytokines on ulcers of lower limb and the mediating role of metabolites in the association between inflammatory cytokines and ulcers of lower limb.

Therapeutic potential of roxadustat in immune thrombocytopenia: A Mendelian randomization analysis.

Background: Immune thrombocytopenia (ITP) is characterized by immune-mediated platelet destruction and impaired megakaryocyte maturation. Hypoxia-inducible factor-1 alpha (HIF-1α), pivotal in the development of megakaryocytes and immune regulation, is downregulated in ITP. Roxadustat, which stabilizes HIF-1α, has emerged as a potential therapeutic drug for ITP that acts by enhancing HIF-1α-mediated megakaryocyte development and modulating immune responses.

Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational study.

Avatrombopag is a newly approved thrombopoietin receptor agonist for second-line treatment of chronic immune thrombocytopenia (ITP) in adults. Our previous study showed its efficacy and safety in a small sample of paediatric ITP patients. However, large samples and long-term data are still lacking.

Microalgal-based urea wastewater treatment with p-Hydroxybenzoic acid enhances resource recovery and mitigates biological risks from Bisphenol A.

Efficient nutrient recovery from source-separated urine is vital for wastewater treatment, with microalgae as a promising solution. However, bisphenol A (BPA) in urine can hinder microalgal resource recovery and pose water quality risks. The role of plant hormones in enhancing microalgal growth and pollutant removal is known, but their impact on BPA-laden urine treatment is not well-studied.